Opioid Peptides Control Dopamine Release in the Pituitary — Different Peptides, Different Effects by Region
Opioid peptides continuously suppress dopamine release in the pituitary gland, with dynorphin, enkephalin, and beta-endorphin showing different potencies in different pituitary regions.
Quick Facts
What This Study Found
Endogenous opioid peptides tonically inhibit dopamine release from both pituitary regions. Opioid peptides show differential potency between the two regions, suggesting different receptor distributions.
Key Numbers
How They Did This
Posterior pituitary and stalk-median eminence from ovariectomized rats were incubated in vitro. Potassium-evoked dopamine release was measured by HPLC after exposure to opioid peptides and naloxone.
Why This Research Matters
Dopamine from the pituitary regulates prolactin and other hormones. Different opioid regulation in different pituitary regions adds precision to hormonal control.
The Bigger Picture
Since pituitary dopamine controls prolactin and other hormones, opioid peptide regulation of this dopamine has downstream effects on lactation, reproductive function, and stress responses. This helps explain why opioid medications commonly cause hormonal side effects.
What This Study Doesn't Tell Us
In-vitro study using isolated tissue. The artificial potassium stimulation does not perfectly mimic natural nerve signaling. Only one species and one hormonal condition (ovariectomized) were tested.
Questions This Raises
- ?Does opioid suppression of pituitary dopamine contribute to hormonal side effects of opioid medications?
- ?Are these opioid-dopamine interactions altered in conditions like hyperprolactinemia?
Trust & Context
- Key Stat:
- Naloxone: +55% dopamine release Blocking opioid receptors boosted pituitary dopamine by 55%, proving opioid peptides constantly suppress dopamine output
- Evidence Grade:
- Preliminary in-vitro study using rat pituitary tissue. Clear quantitative results but artificial stimulation conditions.
- Study Age:
- Published in 1990. The opioid-dopamine interaction in pituitary hormone regulation is now well-established in clinical endocrinology.
- Original Title:
- Regulation of dopamine release in vitro from the posterior pituitary by opioid peptides.
- Published In:
- Neuroendocrinology, 52(4), 399-404 (1990)
- Authors:
- Garris, P A, Ben-Jonathan, N
- Database ID:
- RPEP-00157
Evidence Hierarchy
Frequently Asked Questions
Why does suppressing dopamine matter for hormones?
Dopamine in the pituitary normally inhibits prolactin release. When opioid peptides suppress dopamine, prolactin goes up. This is why opioid medications can cause elevated prolactin levels and associated symptoms.
Why are the effects different in different pituitary regions?
Different pituitary regions express different mixes of opioid receptor types (mu, delta, kappa). Dynorphin targets kappa receptors, enkephalins target delta, and beta-endorphin targets mu — their different distributions explain the region-specific effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00157APA
Garris, P A; Ben-Jonathan, N. (1990). Regulation of dopamine release in vitro from the posterior pituitary by opioid peptides.. Neuroendocrinology, 52(4), 399-404.
MLA
Garris, P A, et al. "Regulation of dopamine release in vitro from the posterior pituitary by opioid peptides.." Neuroendocrinology, 1990.
RethinkPeptides
RethinkPeptides Research Database. "Regulation of dopamine release in vitro from the posterior p..." RPEP-00157. Retrieved from https://rethinkpeptides.com/research/garris-1990-regulation-of-dopamine-release
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.